What Does GLP-2/Tirz Dissolve In? Solvents Explained
Solubility behaviour is where compounds in this library differ most sharply from one another. For GLP-2/Tirz, the determining factors are structural: lipidated dual receptor agonist (gip / glp-1), 39-residue chain.
Overview
Dissolves well, but like all molecules with a fatty chain attached it behaves somewhat like soap — clustering together and frothing if disturbed. Patience is the technique. Let it sit and swirl rather than agitating it.
What GLP-2/Tirz actually is
GLP-2/Tirz is an engineered molecule acting on two receptors in the gut-hormone system involved in blood-sugar regulation. It carries a design detail that is very widely misreported: it was built on a GIP backbone and then modified to also engage GLP-1, whereas most compounds in its class went the other way round.
Supplied for laboratory research use only — not for human or animal use.
Third-party tested by HPLC and LC-MS, ≥99% purity, with a Certificate of Analysis on every order. Ships across Canada.
Technical detail below
How GLP-2/Tirz behaves in solution
Dissolves well but shares the amphiphilic behaviour of all lipidated peptides — prone to foaming, self-associating at higher concentrations. Allow several minutes of gentle swirling rather than forcing dissolution.
Commonly worked at 5–10 mg/mL.
Suitable solvents, in order
Structural basis
GLP-2/Tirz is lipidated dual receptor agonist (gip / glp-1), 39-residue chain. GLP-2/Tirz is built on a GIP-based backbone rather than a GLP-1 one — an important and often-missed design detail. It was engineered from the GIP sequence and modified to acquire GLP-1 receptor activity, with a C20 fatty diacid attached via a linker for albumin binding. The term "twincretin" describes the dual incretin activity.
What GLP-2/Tirz is studied for
Simultaneous GIP and GLP-1 receptor activity from a GIP-derived backbone.
Core metabolic research endpoints for the incretin class.
A well-characterised GLP-1 pathway effect studied in metabolic models.
Whether GIP agonism or antagonism is the productive direction remains an active research debate.
Summarizes published preclinical literature — see the selected references below. Provided for research reference only; not a claim of efficacy or a description of human use.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. GLP-2/Tirz Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
- Browse current GLP-2/Tirz literature on PubMed
References describe in-vitro and preclinical research and are listed for reference only — not evidence of efficacy and not a description of human use.
More GLP-2/Tirz reference
Lyophilized and reconstituted storage conditions, plus the practical working window.
Diluent selection, dissolution behaviour, and the calculator preset for this compound.
The specific chemical routes by which this molecule breaks down, and how to limit each.
Which assays are informative for this molecule, and what to actually check on its COA.
Compound-specific bench practices, and the errors most often made with this molecule.
What to inspect on arrival, and which conditions actually warrant rejecting a vial.
Questions specific to this compound — structure, chemistry, and common misconceptions.
Solubility reference for other compounds
Reviewed for research-use compliance by Kobi Williams, Founder — Popular Peptides Canada. Last reviewed 22 July 2026.
GLP-2/Tirz is supplied strictly as a research chemical for in-vitro laboratory and research use only. It is not intended for human or animal consumption, diagnostic, or therapeutic use. This page is educational laboratory-handling reference information — not medical advice, not usage guidance, and not a protocol.